IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells

Jun Won Lee, Ho Yeon Chung, Lori A. Ehrlich, Diane F. Jelinek, Natalie S. Callander, G. David Roodman, Sun Jin Choi

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

Macrophage inflammatory protein-1α (MIP-1α) gene expression is abnormally regulated in multiple myeloma (MM) owing to imbalanced expression of the acute myeloid leukemia-1A (AML-1A) and AML-1B transcription factors. We hypothesized that the increased expression ratios of AML-1A to AML-1B also induced abnormal expression of other hematopoietic and bone-specific genes that contribute to the poor prognosis of MM patients with high levels of MIP-1α. We found that interleukin-3 (IL-3) was also induced by the imbalanced AML-1A and AML-1B expression in myeloma. IL-3 mRNA levels were increased in CD138+ purified myeloma cells with increased AML-1A-to-AML-1B expression from MM patients, and IL-3 protein levels were significantly increased in freshly isolated bone marrow plasma from MM patients (66.4 ± 12 versus 22.1 ± 8.2 pg/mL; P = .038). IL-3 in combination with MIP-1α or receptor activator of nuclear factor-kappa B ligand (RANKL) significantly enhanced human osteoclast (OCL) formation and bone resorption compared with MIP-1α or RANKL alone. IL-3 stimulated the growth of interleukin-6 (IL-6)-dependent and IL-6-independent myeloma cells in the absence of IL-6, even though IL-3 did not induce IL-6 expression by myeloma cells. These data suggest that increased IL-3 levels in the bone marrow microenvironment of MM patients with imbalanced AML-1A and AML-1B expression can increase bone destruction and tumor cell growth.

Original languageEnglish (US)
Pages (from-to)2308-2315
Number of pages8
JournalBlood
Volume103
Issue number6
DOIs
StatePublished - Mar 15 2004
Externally publishedYes

Fingerprint

Interleukin-3
Osteoclasts
Macrophage Inflammatory Proteins
Multiple Myeloma
Acute Myeloid Leukemia
Bone
Growth
Interleukin-6
RANK Ligand
Bone Marrow
Bone and Bones
Cell growth
Bone Resorption
Gene expression
Tumors
Transcription Factors
Genes
Plasmas
Gene Expression
Messenger RNA

ASJC Scopus subject areas

  • Hematology

Cite this

Lee, J. W., Chung, H. Y., Ehrlich, L. A., Jelinek, D. F., Callander, N. S., Roodman, G. D., & Choi, S. J. (2004). IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood, 103(6), 2308-2315. https://doi.org/10.1182/blood-2003-06-1992

IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. / Lee, Jun Won; Chung, Ho Yeon; Ehrlich, Lori A.; Jelinek, Diane F.; Callander, Natalie S.; Roodman, G. David; Choi, Sun Jin.

In: Blood, Vol. 103, No. 6, 15.03.2004, p. 2308-2315.

Research output: Contribution to journalArticle

Lee, JW, Chung, HY, Ehrlich, LA, Jelinek, DF, Callander, NS, Roodman, GD & Choi, SJ 2004, 'IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells', Blood, vol. 103, no. 6, pp. 2308-2315. https://doi.org/10.1182/blood-2003-06-1992
Lee, Jun Won ; Chung, Ho Yeon ; Ehrlich, Lori A. ; Jelinek, Diane F. ; Callander, Natalie S. ; Roodman, G. David ; Choi, Sun Jin. / IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. In: Blood. 2004 ; Vol. 103, No. 6. pp. 2308-2315.
@article{80b247636c264d3181a69aeec9cfd05e,
title = "IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells",
abstract = "Macrophage inflammatory protein-1α (MIP-1α) gene expression is abnormally regulated in multiple myeloma (MM) owing to imbalanced expression of the acute myeloid leukemia-1A (AML-1A) and AML-1B transcription factors. We hypothesized that the increased expression ratios of AML-1A to AML-1B also induced abnormal expression of other hematopoietic and bone-specific genes that contribute to the poor prognosis of MM patients with high levels of MIP-1α. We found that interleukin-3 (IL-3) was also induced by the imbalanced AML-1A and AML-1B expression in myeloma. IL-3 mRNA levels were increased in CD138+ purified myeloma cells with increased AML-1A-to-AML-1B expression from MM patients, and IL-3 protein levels were significantly increased in freshly isolated bone marrow plasma from MM patients (66.4 ± 12 versus 22.1 ± 8.2 pg/mL; P = .038). IL-3 in combination with MIP-1α or receptor activator of nuclear factor-kappa B ligand (RANKL) significantly enhanced human osteoclast (OCL) formation and bone resorption compared with MIP-1α or RANKL alone. IL-3 stimulated the growth of interleukin-6 (IL-6)-dependent and IL-6-independent myeloma cells in the absence of IL-6, even though IL-3 did not induce IL-6 expression by myeloma cells. These data suggest that increased IL-3 levels in the bone marrow microenvironment of MM patients with imbalanced AML-1A and AML-1B expression can increase bone destruction and tumor cell growth.",
author = "Lee, {Jun Won} and Chung, {Ho Yeon} and Ehrlich, {Lori A.} and Jelinek, {Diane F.} and Callander, {Natalie S.} and Roodman, {G. David} and Choi, {Sun Jin}",
year = "2004",
month = "3",
day = "15",
doi = "10.1182/blood-2003-06-1992",
language = "English (US)",
volume = "103",
pages = "2308--2315",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells

AU - Lee, Jun Won

AU - Chung, Ho Yeon

AU - Ehrlich, Lori A.

AU - Jelinek, Diane F.

AU - Callander, Natalie S.

AU - Roodman, G. David

AU - Choi, Sun Jin

PY - 2004/3/15

Y1 - 2004/3/15

N2 - Macrophage inflammatory protein-1α (MIP-1α) gene expression is abnormally regulated in multiple myeloma (MM) owing to imbalanced expression of the acute myeloid leukemia-1A (AML-1A) and AML-1B transcription factors. We hypothesized that the increased expression ratios of AML-1A to AML-1B also induced abnormal expression of other hematopoietic and bone-specific genes that contribute to the poor prognosis of MM patients with high levels of MIP-1α. We found that interleukin-3 (IL-3) was also induced by the imbalanced AML-1A and AML-1B expression in myeloma. IL-3 mRNA levels were increased in CD138+ purified myeloma cells with increased AML-1A-to-AML-1B expression from MM patients, and IL-3 protein levels were significantly increased in freshly isolated bone marrow plasma from MM patients (66.4 ± 12 versus 22.1 ± 8.2 pg/mL; P = .038). IL-3 in combination with MIP-1α or receptor activator of nuclear factor-kappa B ligand (RANKL) significantly enhanced human osteoclast (OCL) formation and bone resorption compared with MIP-1α or RANKL alone. IL-3 stimulated the growth of interleukin-6 (IL-6)-dependent and IL-6-independent myeloma cells in the absence of IL-6, even though IL-3 did not induce IL-6 expression by myeloma cells. These data suggest that increased IL-3 levels in the bone marrow microenvironment of MM patients with imbalanced AML-1A and AML-1B expression can increase bone destruction and tumor cell growth.

AB - Macrophage inflammatory protein-1α (MIP-1α) gene expression is abnormally regulated in multiple myeloma (MM) owing to imbalanced expression of the acute myeloid leukemia-1A (AML-1A) and AML-1B transcription factors. We hypothesized that the increased expression ratios of AML-1A to AML-1B also induced abnormal expression of other hematopoietic and bone-specific genes that contribute to the poor prognosis of MM patients with high levels of MIP-1α. We found that interleukin-3 (IL-3) was also induced by the imbalanced AML-1A and AML-1B expression in myeloma. IL-3 mRNA levels were increased in CD138+ purified myeloma cells with increased AML-1A-to-AML-1B expression from MM patients, and IL-3 protein levels were significantly increased in freshly isolated bone marrow plasma from MM patients (66.4 ± 12 versus 22.1 ± 8.2 pg/mL; P = .038). IL-3 in combination with MIP-1α or receptor activator of nuclear factor-kappa B ligand (RANKL) significantly enhanced human osteoclast (OCL) formation and bone resorption compared with MIP-1α or RANKL alone. IL-3 stimulated the growth of interleukin-6 (IL-6)-dependent and IL-6-independent myeloma cells in the absence of IL-6, even though IL-3 did not induce IL-6 expression by myeloma cells. These data suggest that increased IL-3 levels in the bone marrow microenvironment of MM patients with imbalanced AML-1A and AML-1B expression can increase bone destruction and tumor cell growth.

UR - http://www.scopus.com/inward/record.url?scp=1542313900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542313900&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-06-1992

DO - 10.1182/blood-2003-06-1992

M3 - Article

C2 - 14615378

AN - SCOPUS:1542313900

VL - 103

SP - 2308

EP - 2315

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -